Pt Vale Indonesa Unsp/Adr (PTNDY) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you for those who join Northline and Northline as well. Welcome to Pediatrics in Asia 2025. I'm Sandro Adi and I will be the moderator of today's call. So with me now, we have, I think most of the C-level from your company, while some of them also join online. Q&A session. So during the session, we will share some key highlights about our company from 2025 and then also providing some 2016 outlook. And that includes any operational milestones, financials and updates on our growth projects. Next one. Okay, so today's agenda will be divided into five agendas. So number one, part one is 2021 challenges, and our part forward will be presented by Pantor Orsio, and then followed by a presentation from Pak Budi Awansya, so a bit on the sustainability. And then part two and three, the operational and growth project updates will be presented by Pak Sil, And then part four will be presented by our CFO, Prisky, and so results. And then part five will be presented again by our CEO, Pantori. Next one, so just a reminder that this presentation and discussion comprise assumptions. Again, just for a reminder, I encourage all of you to, should you have any questions, just put it on the Q&A window, and then we can address those questions after the presentation. So, without further ado, I will now hand the session to Baron Cermanto to begin today's presentation. Yeah, so thank you, Andrew. Hi, everyone. Morning. So, let me begin with a quick recap of 2025, a year where Invalid demonstrated resilience, discipline and also strategy execution despite the dynamic market environment. First of all, I think we successfully strengthened our operational foundation, delivering stable nickel mass production. So we actually exceeded the target of nickel mass production last year, while maint...